PROGRESSIVE SUPRANUCLEAR PALSY

This study tested an experimental drug called AMX0035 in 139 people with progressive supranuclear palsy (PSP), a rare brain disease that affects movement and thinking. The goal was to see if the drug could slow down the disease. Participants received either the drug or a placebo,…

This study looked at the long-term safety of a drug called GV1001 in people with progressive supranuclear palsy (PSP), a rare brain disorder that affects movement and balance. Researchers followed 67 patients who had already completed a previous GV1001 study for an additional 12 …

This study tested a new drug called TPN-101 in 42 people with progressive supranuclear palsy (PSP), a rare brain disease that affects movement and thinking. The main goal was to see if the drug is safe and tolerable over 48 weeks. Researchers also looked at how the drug moves in …

This study tested a drug called GV1001 in 78 people with Progressive Supranuclear Palsy (PSP), a rare brain disease that affects movement and thinking. Participants received daily injections of either a low dose, a high dose, or a placebo for 6 months. The goal was to see if the …

This study looked at how the front part of the brain helps with reasoning and categorizing things. Researchers compared healthy volunteers to people with frontotemporal dementia or progressive supranuclear palsy. They used tasks, brain scans, and mild brain stimulation to underst…